Do Health Inspectors Check Daily Exercise High Authority Revealed

Eligibility for Reimbursement of Anti-Obesity Medications Expands in France

Starting Monday, June 15, 2026, the French National Health Insurance system will cover the cost of Wegovy (semaglutide) and Mounjaro (tirzeglibide) for eligible patients, according to a directive from the Haute Autorité de Santé (HAS). This decision follows a review of clinical data and cost-effectiveness analyses, marking a significant shift in public health policy for obesity management.

Key Clinical Takeaways:

• Reimbursement applies to patients with a BMI ≥30 or ≥27 with comorbidities, requiring a structured weight-management plan.
• Clinical trials demonstrate a 15-20% average weight loss over 68 weeks, with side effects primarily gastrointestinal.
• HAS mandates annual reassessment to ensure adherence to lifestyle interventions alongside pharmacotherapy.

The reimbursement policy, effective June 15, 2026, targets individuals with obesity classified as a chronic disease under the International Classification of Diseases (ICD-11). Eligibility criteria include a body mass index (BMI) of 30 or higher, or 27-29.9 with comorbidities such as type 2 diabetes, hypertension, or sleep apnea. Patients must also engage in a supervised lifestyle intervention program, including dietary counseling and physical activity, as outlined in the HAS guidelines.

Eligibility Criteria for Reimbursement

According to the HAS technical report, patients must first consult a specialist in endocrinology or bariatric medicine for a comprehensive evaluation. “The goal is not to replace lifestyle changes but to augment them,” stated Dr. Claire Martin, an endocrinologist at Paris Descartes University. “These medications are not a substitute for healthy habits but a tool to support long-term weight management.”

Clinical data from the STEP 1 and STEP 4 trials, published in *The New England Journal of Medicine*, show that semaglutide (Wegovy) achieved an average weight loss of 14.9% over 68 weeks, while tirzeglibide (Mounjaro) demonstrated a 12.5% reduction in a Phase III study. Both drugs are administered via weekly subcutaneous injection and are contraindicated in patients with a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Clinical Efficacy and Safety Profiles

The HAS emphasized that reimbursement is contingent on patient adherence to a multidisciplinary care plan. “We are not simply prescribing a pill,” said Dr. Antoine Dubois, a public health researcher at the Institut Pasteur. “The success of these therapies hinges on integrating them into a broader strategy that includes nutritional counseling, behavioral therapy, and regular monitoring.”

A 2025 meta-analysis in *JAMA Internal Medicine* found that GLP-1 receptor agonists like semaglutide reduce cardiovascular risk by 18% in obese patients with type 2 diabetes. However, the same study noted a 5% incidence of severe gastrointestinal side effects, prompting recommendations for gradual dose titration and patient education.

Funding for the HAS evaluation came from the French Ministry of Health, with additional support from the European Medicines Agency (EMA) and the National Institutes of Health (NIH). The EMA’s 2024 guideline on anti-obesity therapies underscored the importance of long-term safety data, noting that “current evidence supports short- to medium-term use but highlights the need for ongoing surveillance.”

Public Health Implications and Regulatory Considerations

The expansion of reimbursement aligns with global efforts to address the obesity epidemic. The World Health Organization (WHO) reported that 650 million adults worldwide had obesity in 2023, with associated healthcare costs exceeding $2 trillion annually. In France, obesity prevalence stands at 18.5%, according to the 2025 INSEE survey, with 6.3% of children aged 3-17 classified as obese.

Despite the policy shift, concerns persist about equitable access. A 2026 audit by the French Medical Council found that only 12% of primary care physicians had received specialized training in obesity management, raising questions about the scalability of the new guidelines. “We need to ensure that both providers and patients are adequately prepared,” said Dr. Élodie Rousseau, a pediatric endocrinologist at Hôpital Necker-Enfants Malades.

For healthcare providers, the updated reimbursement rules necessitate adherence to strict documentation protocols. Clinics offering obesity care must now submit quarterly reports to the National Health Insurance Agency, detailing patient progress and compliance with lifestyle recommendations. Failure to meet these requirements could result in suspended coverage for non-adherent patients.

Directory Bridge: Connecting Patients to Specialized Care

Patients seeking treatment should consult with board-certified endocrinologists or specialized weight-management clinics to develop a personalized care plan. These professionals can navigate the reimbursement process and ensure compliance with HAS guidelines.

Pharmaceutical companies and distributors must also adapt to the new framework. Healthcare compliance attorneys are advising manufacturers on aligning with the updated reimbursement criteria, particularly regarding patient monitoring and data reporting requirements.

The integration of anti-obesity medications into public health systems reflects a broader shift toward precision medicine. As Dr. Martin noted, “These therapies are not a one-size-fits-all solution. They require careful patient selection and ongoing support to achieve sustainable outcomes.”

Looking ahead, the HAS plans to reassess the policy in 2027, incorporating real-world data on long-term efficacy and safety. Until then, healthcare providers and patients must navigate the evolving landscape of obesity treatment with a focus on evidence-based practices and patient-centered care.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.